Supernus Pharma Stock Price, News & Analysis

Supernus Pharmaceuticals (NASDAQ: SUPN) announced the expiration of the Hart-Scott-Rodino waiting period for its proposed acquisition of Sage Therapeutics (NASDAQ: SAGE). The tender offer includes a cash payment of $8.50 per share plus one non-transferable contingent value right (CVR) worth up to $3.50 per share based on milestone achievements.

The CVR milestones include: $0.50 for ZURZUVAE's first commercial sale in Japan by June 2026, $1.00 for U.S. sales exceeding $250M by 2027, $1.00 for U.S. sales over $300M by 2028, and $1.00 for U.S. sales surpassing $375M by 2030. The tender offer expires on July 30, 2025, after which Supernus plans to complete the acquisition through a merger, making Sage its wholly owned subsidiary.

Supernus Pharmaceuticals (Nasdaq: SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, has scheduled its second quarter 2025 financial results announcement for August 5, 2025, after market close.

The company will host a conference call at 4:30 p.m. ET on the same day, featuring CEO Jack Khattar and CFO Tim Dec. The presentation will be available via webcast through the company's investor relations website, with a replay accessible for 60 days following the event.

Supernus Pharmaceuticals (SUPN) announced the acquisition of Sage Therapeutics for a total consideration of up to $795 million ($12.00 per share), comprising $8.50 per share in cash upfront and a CVR worth up to $3.50 per share. The deal includes ZURZUVAE, the first FDA-approved oral medicine for postpartum depression, which generated collaboration revenue of $36.1M in 2024 and $13.8M in Q1 2025. Through a partnership with Biogen, Supernus will receive 50% of ZURZUVAE's U.S. net revenue. The acquisition is expected to close in Q3 2025, promising cost synergies of up to $200M annually and significant accretion in 2026. The CVR includes milestones tied to ZURZUVAE sales targets ranging from $250M to $375M and Japanese market entry.

Supernus Pharmaceuticals (SUPN) is expanding its partnership with TV personality Jay Glazer and his wife Rosie in a new content series about ADHD and relationships. The four-part video series, launching on the All About ADHD YouTube channel in May 2025, explores how Qelbree (viloxazine extended-release capsules), a non-stimulant ADHD treatment, has helped Jay manage his symptoms. The series aims to provide insights into the challenges and successes of couples affected by ADHD, with Jay sharing his experience using Qelbree and Rosie discussing her supporting role. The first episode, "Jay & Rosie Glazer's ADHD Story: Real Life, Real Change," is now available. Qelbree is approved for ADHD treatment in adults and children 6 years and older, with important safety information including potential increased risk of suicidal thoughts and actions.

Supernus Pharmaceuticals (NASDAQ: SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, announced its participation in the 2025 Jefferies Global Healthcare Conference. President and CEO Jack A. Khattar will engage in a fireside chat on June 4, 2025, at 2:00 p.m. ET in New York City.

Investors can arrange meetings with management through the Jefferies conference coordinator. The presentation will be available via live audio webcast, accessible through the company's website, with a replay available for 60 days post-conference.

Supernus Pharmaceuticals (SUPN) has received Paragraph IV Notice Letters regarding Abbreviated New Drug Applications (ANDAs) from third parties for its drug Qelbree (viloxazine extended-release capsules) in 100, 150, and 200 mg base formulations. The company plans to vigorously defend its intellectual property rights for Qelbree, which is protected by six U.S. patents listed in the FDA's Orange Book. Three patents expire in September 2029, two in February 2033, and one in April 2035.

Supernus Pharmaceuticals (SUPN) has launched 'Ms. Represented,' a groundbreaking campaign featuring actress Busy Philipps to raise awareness about ADHD in women. The campaign highlights how females often present different ADHD symptoms than males, focusing on inattentive symptoms rather than hyperactivity. Due to this difference, boys are twice as likely to be diagnosed with ADHD than girls, leaving many women undiagnosed or untreated.

The campaign promotes Qelbree®, Supernus's once-daily non-stimulant ADHD treatment for patients 6 years and older. As the first non-stimulant approved for adults with ADHD in 20 years, Qelbree has no evidence of abuse potential and offers convenient prescription refills. The initiative, launched during Mental Health Awareness Month on Bustle, aims to empower women to recognize their ADHD symptoms and seek proper medical attention.

Supernus Pharmaceuticals (SUPN) reported mixed Q1 2025 financial results with total revenues increasing 4% to $149.8 million. Key highlights include Qelbree sales growing 44% to $64.7 million and GOCOVRI sales rising 16% to $30.7 million. However, the company posted an operating loss of $(10.3) million compared to $(3.2) million in 2024. The company launched ONAPGO for Parkinson's disease in April 2025. Qelbree showed strong prescription growth with 214,908 total prescriptions, up 22% YoY. The pipeline includes ongoing trials for SPN-817 (epilepsy), SPN-820 (depression), and SPN-443 (ADHD/CNS). Supernus maintains its 2025 guidance with total revenues of $600-$630 million and adjusted operating earnings of $105-$130 million.

Supernus Pharmaceuticals (SUPN) has scheduled its first quarter 2025 financial results announcement for Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day, featuring President and CEO Jack Khattar and Senior VP and CFO Tim Dec.

The presentation will include Q1 2025 financial and business results, followed by a Q&A session. Investors can access the live webcast through the Events & Presentations section of Supernus' Investor Relations website. Pre-registration is available for participants, who will receive a personalized conference code. A replay will be available on the company's website for 60 days following the live call.